Top Page
China Reinsurance (Group) Corp. Class H
(1508)
China Reinsurance (Group) Corp. Class H (1508) vs. iShares MSCI Hong Kong ETF (EWH)
China Reinsurance (Group) Corp. Class H Business Overview & Revenue Model
China Reinsurance (Group) Corp. Class H Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 85.54B | 94.96B | 88.27B | 163.95B | 168.10B |
| Gross Profit | 85.54B | 94.96B | 80.06B | 163.95B | 168.10B |
| EBITDA | 17.04B | 9.95B | 1.85B | 10.38B | 10.25B |
| Net Income | 10.56B | 5.65B | -324.64M | 5.95B | 5.71B |
Balance Sheet | |||||
| Total Assets | 508.35B | 459.73B | 424.73B | 499.80B | 453.58B |
| Cash, Cash Equivalents and Short-Term Investments | 13.01B | 10.30B | 10.97B | 18.74B | 10.22B |
| Total Debt | 13.97B | 15.43B | 17.96B | 27.46B | 27.79B |
| Total Liabilities | 395.68B | 357.55B | 327.24B | 397.71B | 350.68B |
| Stockholders Equity | 103.26B | 93.25B | 86.02B | 92.71B | 93.03B |
Cash Flow | |||||
| Free Cash Flow | 9.91B | 15.86B | 11.31B | 9.12B | 32.34B |
| Operating Cash Flow | 10.35B | 16.29B | 11.71B | 9.56B | 33.24B |
| Investing Cash Flow | -18.56B | -14.83B | -6.80B | -15.57B | -47.34B |
| Financing Cash Flow | 4.62B | 999.20M | -12.20B | 14.01B | 7.96B |
China Reinsurance (Group) Corp. Class H Technical Analysis
China Reinsurance (Group) Corp. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $61.03B | 7.47 | 10.74% | 2.01% | 23.64% | 36.32% | |
| ― | HK$52.83B | 7.19 | 9.76% | 5.25% | 8.20% | 42.29% | |
| ― | €67.12B | 5.58 | 11.12% | 3.44% | 2.54% | 17.80% | |
| ― | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
| ― | €27.33B | 18.18 | 6.00% | ― | -2.69% | -68.97% | |
| ― | HK$88.77B | 15.73 | 5.22% | 2.20% | 30.38% | 2.63% | |
| ― | €20.05B | 25.20 | 7.22% | ― | 19.01% | 64.43% |
China Reinsurance (Group) Corp. Class H Corporate Events
China Reinsurance (Group) Corporation has announced a change in its agent for the acceptance of service of process in Hong Kong due to the retirement of Ms. Luo Yawei. Effective from September 26, 2025, Mr. Zhou Jun will replace Ms. Luo Yawei as the new Process Agent, ensuring continuity in compliance with Hong Kong’s regulatory requirements.
The most recent analyst rating on (HK:1508) stock is a Buy with a HK$2.10 price target. To see the full list of analyst forecasts on China Reinsurance (Group) Corp. Class H stock, see the HK:1508 Stock Forecast page.
China Reinsurance (Group) Corporation announced that its subsidiary, China Re P&C, has received regulatory approvals to issue 10-year redeemable capital supplementary bonds up to RMB4.0 billion in the National Interbank Bond Market. This move is expected to enhance the company’s solvency and support the sustainable growth of its business operations.
The most recent analyst rating on (HK:1508) stock is a Buy with a HK$2.10 price target. To see the full list of analyst forecasts on China Reinsurance (Group) Corp. Class H stock, see the HK:1508 Stock Forecast page.
China Reinsurance (Group) Corporation announced significant leadership changes with the resignation of Mr. He Chunlei as chairman of the board and executive director due to reaching the statutory retirement age. Mr. Zhuang Qianzhi has been appointed as the new chairman of the board, pending approval from the National Financial Regulatory Administration. These changes are expected to influence the company’s strategic direction and operational leadership, potentially impacting its market positioning and stakeholder relations.
The most recent analyst rating on (HK:1508) stock is a Buy with a HK$2.10 price target. To see the full list of analyst forecasts on China Reinsurance (Group) Corp. Class H stock, see the HK:1508 Stock Forecast page.
China Reinsurance (Group) Corporation announced the composition of its board of directors, which includes eight members with specific roles and functions. The board has established five specialized committees to oversee different aspects of the company’s operations, highlighting a structured approach to governance and strategic oversight.
The most recent analyst rating on (HK:1508) stock is a Buy with a HK$2.10 price target. To see the full list of analyst forecasts on China Reinsurance (Group) Corp. Class H stock, see the HK:1508 Stock Forecast page.
China Reinsurance (Group) Corporation announced the approval of Mr. Keung Yui Fai as an independent non-executive director by the National Financial Regulatory Administration. This approval enables the company to comply with the Hong Kong Stock Exchange’s requirements for board composition, ensuring it has the requisite number of independent non-executive directors. The appointment also addresses previous regulatory compliance issues related to board composition and committee leadership, enhancing the company’s governance structure.
The most recent analyst rating on (HK:1508) stock is a Buy with a HK$2.10 price target. To see the full list of analyst forecasts on China Reinsurance (Group) Corp. Class H stock, see the HK:1508 Stock Forecast page.
China Reinsurance (Group) Corporation has announced the composition of its board of directors, which includes a mix of executive, non-executive, and independent non-executive directors. The board has established five specialized committees to oversee various aspects of the company’s operations, indicating a structured approach to governance and risk management.
The most recent analyst rating on (HK:1508) stock is a Buy with a HK$2.10 price target. To see the full list of analyst forecasts on China Reinsurance (Group) Corp. Class H stock, see the HK:1508 Stock Forecast page.
China Reinsurance (Group) Corporation reported its unaudited interim results for the first half of 2025, showing a net profit increase to RMB 6.6 billion from RMB 5.9 billion in the same period of 2024. The company has adopted new international financial reporting standards, which may influence its financial reporting and operational strategies, potentially impacting stakeholders and its market position.
The most recent analyst rating on (HK:1508) stock is a Buy with a HK$2.10 price target. To see the full list of analyst forecasts on China Reinsurance (Group) Corp. Class H stock, see the HK:1508 Stock Forecast page.
China Reinsurance (Group) Corporation announced the unaudited interim reports and solvency statements for its subsidiaries, China Re P&C and China Re Life, for the first half of 2025. This disclosure is part of the regulatory requirements following the successful issuance of capital supplementary bonds by these subsidiaries, amounting to RMB4.0 billion each for China Re P&C and RMB5.0 billion for China Re Life. The announcement highlights the company’s compliance with financial regulations and its strategic financial maneuvers to strengthen its capital base, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (HK:1508) stock is a Buy with a HK$2.10 price target. To see the full list of analyst forecasts on China Reinsurance (Group) Corp. Class H stock, see the HK:1508 Stock Forecast page.
China Reinsurance (Group) Corporation has announced that its board of directors will meet on August 29, 2025, to consider and approve the interim results for the first half of the year ending June 30, 2025. This meeting is crucial for stakeholders as it will provide insights into the company’s financial performance and strategic decisions for the upcoming period.
The most recent analyst rating on (HK:1508) stock is a Hold with a HK$0.88 price target. To see the full list of analyst forecasts on China Reinsurance (Group) Corp. Class H stock, see the HK:1508 Stock Forecast page.